Reps say training could improve
As pharmaceutical companies rely more on sales representatives, reps say they need more training to help them in their jobs.
According to "Sales Rep Training: A Comparative Analysis â 2001," a new strategic study from Newtown, PA-based Scott-Levin, more than 80% of reps find their initial training effective, and 75% say the same for advanced training.
However, 40% of reps think their companies should invest more in training programs, and many also want more hands-on experience. Ninety percent say new-rep training programs include field time with district managers and experienced reps, but 72% say most of their time is spent in the classroom. Sixty-two percent say they would benefit from increased field training.
In addition, 60% of reps want more technology-based instruction, such as CD-ROMs and Web-based training.
Other results
The study also found that:
• Reps say the best-trained sales forces are from New York-based Pfizer Inc. and Merck & Co. Inc., Whitehouse Station, NJ.
• Reps from Philadelphia-based Smith-Kline Beecham and Pfizer rate their training as above average, while Parsippany, NJ-based Aventis Pharma AG earns higher-than-average marks for its advanced training.
• The topics most frequently covered for new reps include product knowledge, disease knowledge and management, professional selling skills, and anatomy and physiology.
• Advanced trainees rate professional selling skills as the most popular topic.
The report was based on responses from more than 900 reps from 20 companies. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
